Trial Watch; April Edition 8
Where Conviction Is Building, In Real Time
The second half of April 2026 shows three clear signals; oncology programs are moving into direct competitive tests, PAH and obesity remain active cardiometabolic frontiers, and autoimmune cell therapy is moving from early excitement into industrial validation. The strongest signals are BMS moving CD19 CAR-T into Phase 3 systemic sclerosis, Roche testing NXT007 against its own Hemlibra franchise, Janssen running an IL-23 head-to-head trial in Crohn's disease, and HELP Therapeutics taking iPSC-derived cardiomyocytes into advanced heart failure.
Therapeutic Areas Covered
Oncology
4 trialsSacituzumab tirumotecan (MK-2870-031); Phase 3 in pretreated urothelial carcinoma
TROP2-directed antibody-drug conjugate carrying a topoisomerase-1 inhibitor payload
Timeline
Start: April 30, 2026. Primary completion: July 2029.
Mechanism
Sacituzumab tirumotecan is a TROP2-directed antibody-drug conjugate carrying a topoisomerase-1 inhibitor payload. The study compares MK-2870 with investigator-choice non-platinum chemotherapy in pretreated locally advanced or metastatic urothelial carcinoma.
Why It Matters
Merck is moving a next-generation TROP2 ADC into a pivotal bladder cancer setting. The competitive stake is clear; Gilead has built Trodelvy into the TROP2 ADC conversation, while Seagen and Astellas have shifted expectations in urothelial cancer with enfortumab vedotin. Merck is using a large Phase 3 design to test whether its own ADC can become part of the post-platinum treatment sequence.
Reference layer
PF-08634404; Phase 2/3 in untreated advanced gastric, GEJ and esophageal adenocarcinoma
Investigational agent combined with chemotherapy in upper gastrointestinal cancer
Timeline
Start: April 28, 2026. Primary completion: July 2031.
Mechanism
PF-08634404 is being studied with chemotherapy in gastroesophageal cancer. The large seamless Phase 2/3 structure suggests Pfizer is trying to move quickly from signal finding to a registrational path.
Why It Matters
Upper GI cancer is increasingly contested by checkpoint inhibitors, antibody-drug conjugates, and targeted combinations. Pfizer entering with an 840-participant study signals a serious push into a field where Merck, BMS, AstraZeneca, Daiichi Sankyo, and others are already competing for frontline influence.
Reference layer
BREnnA (RO7771950 versus tucatinib); Phase 2/3 in HER2-positive metastatic breast cancer
Blood-brain-barrier penetrant HER2 TKI head-to-head versus tucatinib
Timeline
Start: April 30, 2026. Primary completion: March 2029.
Mechanism
RO7771950 is a blood-brain-barrier penetrant HER2 tyrosine kinase inhibitor being compared with tucatinib, both in combination with trastuzumab and capecitabine. The study includes patients with or without central nervous system metastases.
Why It Matters
This is a direct active-comparator trial against tucatinib, a meaningful standard in HER2-positive breast cancer with CNS involvement. Roche is not testing against placebo; it is testing whether a new CNS-penetrant HER2 inhibitor can compete with an established regimen in one of the hardest parts of HER2 breast cancer care.
VINCIT (visugromab); Phase 2/3 in cancer-associated cachexia
GDF-15 neutralizing monoclonal antibody for advanced cancer-associated cachexia
Timeline
First patient dosed announced April 2026. Primary completion: December 2029.
Mechanism
Visugromab is a monoclonal antibody designed to neutralize GDF-15, a pathway associated with anorexia, fatigue, wasting, and poor outcomes in advanced cancer.
Why It Matters
Cachexia has remained one of oncology's most persistent unmet needs. Pfizer's ponsegromab helped bring GDF-15 biology into focus. CatalYm is now taking the same broad biological thesis into a large adaptive Phase 2/3 program, making this a high-signal supportive oncology trial rather than a narrow symptom-management study.
Cardiometabolic & Cardiopulmonary
4 trialsAMAZE-12 (NNC0487-0111); Phase 3 in obesity
Investigational Novo Nordisk obesity asset for adults with excess body weight
Timeline
Start: April 21, 2026. Primary completion: June 2028.
Mechanism
NNC0487-0111 is an investigational Novo Nordisk obesity asset. The study tests whether the agent is safe and effective for people with excess body weight.
Why It Matters
Novo is defending its obesity position while Eli Lilly continues to set a high bar with tirzepatide and next-generation incretin programs. A 600-participant Phase 3 obesity trial signals that Novo is building beyond first-generation GLP-1 leadership and preparing a broader obesity franchise strategy.
Reference layer
REVIVE-HEART (HiCM-188); Phase 3 iPSC-derived cardiomyocytes in advanced heart failure
Universal iPSC-derived cardiomyocyte cell therapy delivered intramyocardially during CABG
Timeline
Start: April 30, 2026. Primary completion: June 2027.
Mechanism
HiCM-188 is a human induced pluripotent stem cell derived cardiomyocyte product administered by intramyocardial injection in advanced heart failure patients undergoing CABG.
Why It Matters
This is one of the strongest advanced-modality signals in the edition. Heart failure has been dominated by drugs that modify signaling, pressure, or metabolism. REVIVE-HEART tests the more ambitious idea of replacing lost contractile tissue. A Phase 3 iPSC-derived cardiomyocyte study creates a regulatory test case for regenerative cardiology.
PALM-PAH (treprostinil palmitil inhalation powder); Phase 3 in PAH
Once-daily inhaled prodrug of treprostinil for pulmonary arterial hypertension
Timeline
Start: April 17, 2026. Primary completion: December 2028.
Mechanism
Treprostinil palmitil inhalation powder is an inhaled prodrug of treprostinil designed for once-daily pulmonary delivery and longer lung residence.
Why It Matters
The PAH market has effective prostacyclin biology but a major dosing burden. United Therapeutics built a large franchise around inhaled treprostinil. Insmed is trying to change the adherence and convenience equation with once-daily TPIP, turning delivery into a competitive strategy.
Reference layer
ILLUMINATE (REGN13335); Phase 2 in pulmonary arterial hypertension
Anti-PDGF-B antibody targeting vascular remodeling biology in PAH
Timeline
Start: April 30, 2026. Primary completion: March 2028.
Mechanism
REGN13335 is an experimental antibody targeting PDGF-B. The study evaluates safety and efficacy in adults with PAH who are already receiving other PAH medicines.
Why It Matters
PAH therapy has historically focused on vasodilation. REGN13335 is aimed at vascular remodeling biology, a deeper disease mechanism. In the same window that Insmed moved a prostacyclin delivery strategy forward, Regeneron moved a remodeling strategy into Phase 2, showing two very different bets on the future of PAH treatment.
Immunology & Autoimmune
3 trialsPovetacicept; Phase 2 in generalized myasthenia gravis
Dual APRIL and BAFF antagonist targeting B-cell survival and autoantibody production
Timeline
Start: April 16, 2026. Primary completion: March 2029.
Mechanism
Povetacicept is a dual APRIL and BAFF antagonist intended to affect B-cell survival and autoantibody production.
Why It Matters
Vertex is expanding beyond cystic fibrosis into autoimmune disease. Generalized myasthenia gravis has become a competitive proving ground for FcRn blockade, complement inhibition, CAR-T approaches, and B-cell biology. Povetacicept gives Vertex a differentiated plasma cell and autoantibody strategy in a market shaped by argenx, UCB, and emerging cell therapy players.
BI 3000202; Phase 2 in systemic lupus erythematosus
Oral investigational therapy across multiple dose levels versus placebo in SLE
Timeline
Start: April 20, 2026. Primary completion: February 2029.
Mechanism
BI 3000202 is an oral investigational therapy being tested at multiple dose levels against placebo in adults with SLE.
Why It Matters
SLE remains one of the most difficult autoimmune indications to transform. Existing biologics have improved the field but have not solved broad disease control. A 405-participant Phase 2 from Boehringer suggests the company wants a robust dose-finding and proof-of-concept package in a biologics-heavy category where oral convenience could matter.
CHARGE (guselkumab versus risankizumab); Phase 3b in Crohn's disease
Direct head-to-head of two IL-23 p19 antibodies in moderately to severely active Crohn's
Timeline
Planned around late April or early May 2026. Primary completion: November 2028.
Mechanism
CHARGE directly compares guselkumab with risankizumab in moderately to severely active Crohn's disease. Both are IL-23 p19 antibodies.
Why It Matters
This is one of the cleanest strategic trials in the edition. Janssen is not simply proving Tremfya works; it is testing Tremfya against AbbVie's Skyrizi in the same disease class. Head-to-head studies like this are commercial, clinical, and payer strategy at the same time.
Advanced Modalities
3 trialsBreakfree-SSc (BMS-986353 / zola-cel); Phase 3 CD19 CAR-T in systemic sclerosis
CD19-targeted NEX-T CAR-T cell therapy versus standard of care in active systemic sclerosis
Timeline
Start: April 30, 2026. Primary completion: November 2028.
Mechanism
BMS-986353, also called zolacaptagene autoleucel or zola-cel, is a CD19-targeted NEX-T CAR-T cell therapy being compared with standard of care in active systemic sclerosis.
Why It Matters
This is the flagship advanced-modality signal. Autoimmune CAR-T has moved from academic excitement into industrial Phase 3 development. BMS is committing a high-cost cell therapy platform to systemic sclerosis, creating a regulatory and commercial test case for Cabaletta, Kyverna, Cartesian, and other autoimmune cell therapy players.
ZEBRHA-2 (NXT007 versus emicizumab); Phase 3 in hemophilia A
Next-generation FIXa/FX bispecific antibody tested against Roche's own Hemlibra franchise
Timeline
Start: April 30, 2026. Primary completion: February 2028.
Mechanism
NXT007 is a next-generation FIXa and FX bispecific antibody designed to improve on emicizumab prophylaxis in people with hemophilia A.
Why It Matters
Roche is testing a successor against its own Hemlibra franchise. That is a very strong signal of portfolio discipline. Rather than waiting for a competitor to cannibalize Hemlibra, Roche is trying to own the next generation of bispecific prophylaxis itself.
Descartes-08; Phase 2 in autoantibody myositis
Autologous mRNA-engineered BCMA-targeted CAR-T using transient RNA design
Timeline
Start: April 28, 2026. Primary completion: November 2027.
Mechanism
Descartes-08 is an autologous mRNA-engineered CAR-T product targeting BCMA. Its transient RNA design is intended to avoid permanent genomic integration and may allow repeat dosing without the same risk profile as viral vector CAR-T.
Why It Matters
Cartesian represents a different philosophy from conventional CAR-T. While BMS tests persistent CD19 CAR-T in systemic sclerosis, Cartesian is testing a transient mRNA CAR-T approach in autoimmune myositis. Together, these trials show that autoimmune cell therapy is no longer a single-modality story.
Reference layer
Infectious Disease
1 trialGSK3772701; Phase 2A novel antimalarial pyrrolidinamide in uncomplicated P. falciparum malaria
Novel antimalarial chemotype across multiple dose levels and durations
Timeline
Start: April 20, 2026. Primary completion: July 2027.
Mechanism
GSK3772701 is a novel antimalarial pyrrolidinamide being evaluated across multiple dose levels and durations in adults with uncomplicated Plasmodium falciparum malaria.
Why It Matters
Malaria remains a major global health threat, and artemisinin partial resistance has increased the urgency for new chemotypes. GSK staying active in antimalarial development is strategically important because many large pharma companies have reduced anti-infective investment. A novel pyrrolidinamide entering Phase 2A is small in size but meaningful as a public health signal.
Signal Convergence
Autoimmune cell therapy is becoming a real development category
BMS is taking CD19 CAR-T into Phase 3 systemic sclerosis while Cartesian advances a transient mRNA CAR-T model in autoimmune myositis. Vertex adds a third B-cell axis strategy through povetacicept.
Active comparator trials are the clearest sign of confidence
BREnnA, CHARGE, and ZEBRHA-2 are not soft placebo comparisons. They are direct tests against current standards or internal franchise leaders.
PAH is splitting into two strategic paths
Insmed is competing through better prostacyclin delivery, while Regeneron is testing vascular remodeling biology through PDGF-B. The field is no longer only about vasodilation.
Conviction is concentrating around fewer, larger bets
Pfizer, Roche, BMS, Novo Nordisk, Janssen, and Merck are not running small exploratory programs here. They are putting meaningful patient numbers and strategic capital behind specific mechanisms.
About Trial Watch
Trial Watch is Kitsa's clinical intelligence layer. It captures high-signal clinical trial events and interprets where science, capital, and strategy are converging.
Keep exploring
Recommended next
- Blog
11 Early-Phase Trials and Design Frameworks to Reduce Design Risk
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
- Blog
4 AI Misconceptions in Clinical Trials You Cannot Afford to Ignore
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
- Blog
7 Questions to Ask Before Choosing an AI Patient Screening Solution
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
- Glossary
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.